NO821569L - Diagnostiseringsmetode og proevesett - Google Patents

Diagnostiseringsmetode og proevesett

Info

Publication number: NO821569L
Authority: NO; Norway
Prior art keywords: differentiated; antigenic; antigenic components; components; stated
Prior art date: 1980-09-24

Application number

NO821569A

Other languages

English (en)

Norwegian (no)

Inventor

Henry Anthony Erlich

Michael Alan Lovett

Original Assignee

Cetus Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-09-24

Filing date

1982-05-12

Publication date

1982-05-12

1982-05-12 Application filed by Cetus Corp filed Critical Cetus Corp

1982-05-12 Publication of NO821569L publication Critical patent/NO821569L/no

Links

238000000034 method Methods 0.000 title claims description 40
238000012360 testing method Methods 0.000 title claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 85
102000004169 proteins and genes Human genes 0.000 claims description 70
230000000890 antigenic effect Effects 0.000 claims description 67
201000010099 disease Diseases 0.000 claims description 59
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
210000002966 serum Anatomy 0.000 claims description 43
238000006243 chemical reaction Methods 0.000 claims description 40
241000589884 Treponema pallidum Species 0.000 claims description 28
239000000758 substrate Substances 0.000 claims description 27
206010020751 Hypersensitivity Diseases 0.000 claims description 22
230000007815 allergy Effects 0.000 claims description 22
208000026935 allergic disease Diseases 0.000 claims description 21
238000003745 diagnosis Methods 0.000 claims description 19
150000004676 glycans Chemical class 0.000 claims description 14
229920001282 polysaccharide Polymers 0.000 claims description 14
239000005017 polysaccharide Substances 0.000 claims description 14
239000007787 solid Substances 0.000 claims description 11
238000012546 transfer Methods 0.000 claims description 9
238000001155 isoelectric focusing Methods 0.000 claims description 7
244000005700 microbiome Species 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 6
244000052769 pathogen Species 0.000 claims description 6
230000001717 pathogenic effect Effects 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 4
239000013566 allergen Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
238000001502 gel electrophoresis Methods 0.000 claims 3
239000000499 gel Substances 0.000 description 45
239000000427 antigen Substances 0.000 description 26
102000036639 antigens Human genes 0.000 description 24
108091007433 antigens Proteins 0.000 description 24
238000000211 autoradiogram Methods 0.000 description 22
208000006379 syphilis Diseases 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
201000005485 Toxoplasmosis Diseases 0.000 description 10
238000001962 electrophoresis Methods 0.000 description 10
229920002401 polyacrylamide Polymers 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
239000000523 sample Substances 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 9
241000223996 Toxoplasma Species 0.000 description 9
241000223997 Toxoplasma gondii Species 0.000 description 8
238000001514 detection method Methods 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
241001529453 unidentified herpesvirus Species 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
230000001154 acute effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
239000000020 Nitrocellulose Substances 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 6
ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 6
238000000376 autoradiography Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
229910052740 iodine Inorganic materials 0.000 description 6
239000011630 iodine Substances 0.000 description 6
229920001220 nitrocellulos Polymers 0.000 description 6
229940079938 nitrocellulose Drugs 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
241000606161 Chlamydia Species 0.000 description 5
241000606153 Chlamydia trachomatis Species 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
108010058846 Ovalbumin Proteins 0.000 description 4
241000700584 Simplexvirus Species 0.000 description 4
238000013019 agitation Methods 0.000 description 4
239000003659 bee venom Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
229940092253 ovalbumin Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
229910001870 ammonium persulfate Inorganic materials 0.000 description 3
238000003149 assay kit Methods 0.000 description 3
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
239000004327 boric acid Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000012631 diagnostic technique Methods 0.000 description 3
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
239000002245 particle Substances 0.000 description 3
208000009090 primary syphilis Diseases 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000009589 serological test Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
206010056873 tertiary syphilis Diseases 0.000 description 3
238000005406 washing Methods 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
206010019973 Herpes virus infection Diseases 0.000 description 2
208000008306 Latent Syphilis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
201000000860 Secondary syphilis Diseases 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229940038705 chlamydia trachomatis Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000003599 detergent Substances 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
208000014479 late latent syphilis Diseases 0.000 description 2
239000010410 layer Substances 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
238000002791 soaking Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
241001647378 Chlamydia psittaci Species 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241001197893 Glyptemys herpesvirus Species 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
YBOFEONRFJMHND-UHFFFAOYSA-N [Br].N#CC#N Chemical compound [Br].N#CC#N YBOFEONRFJMHND-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000007374 clinical diagnostic method Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000011229 interlayer Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Virology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)

NO821569A 1980-09-24 1982-05-12 Diagnostiseringsmetode og proevesett NO821569L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19036180A	1980-09-24	1980-09-24
US29796281A	1981-09-02	1981-09-02

Publications (1)

Publication Number	Publication Date
NO821569L true NO821569L (no)	1982-05-12

Family

ID=26886027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO821569A NO821569L (no)	1980-09-24	1982-05-12	Diagnostiseringsmetode og proevesett

Country Status (10)

Country	Link
EP (1)	EP0050424B1 (de)
JP (1)	JPS57501692A (de)
BR (1)	BR8108820A (de)
CA (1)	CA1167376A (de)
DE (1)	DE3172347D1 (de)
DK (1)	DK232882A (de)
ES (1)	ES505713A0 (de)
IL (1)	IL63907A0 (de)
NO (1)	NO821569L (de)
WO (1)	WO1982001011A1 (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0063810B1 (de) *	1981-04-29	1986-03-05	Ciba-Geigy Ag	Prüfmittel und Ausrüstung für immunologische Analysen
FI69639C (fi) *	1982-07-02	1986-03-10	Orion Yhtymae Oy	Preparat foer anvaendning vid klamydia-diagnostik
US4863729A (en) *	1984-06-20	1989-09-05	Linus Pauling Institute Of Science And Medicine	Method for preparing a macromolecular monoclonal antibody composition
US4647544A (en) *	1984-06-25	1987-03-03	Nicoli David F	Immunoassay using optical interference detection
DE3722273A1 (de) *	1986-07-08	1988-01-21	Bio Rad Laboratories	Festphasen-bindungsreagentien, ihre herstellung und sie enthaltende assay-kits
NZ221895A (en) *	1986-09-26	1990-09-26	Univ California	Composition and method for the diagnosis of pseudomonas aeruginosa infections
US6277592B1 (en)	1996-07-31	2001-08-21	Purina Mills, Inc.	Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6297027B1 (en)	1996-07-31	2001-10-02	Purina Mills, Inc.	Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6171788B1 (en)	1997-01-28	2001-01-09	The Regents Of The University Of California	Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en)	1997-01-28	2002-11-05	The Regents Of The University Of California	Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en)	1997-01-28	2006-11-21	The Regents Of The University Of California	Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6103468A (en) *	1997-10-07	2000-08-15	Labatt Brewing Company Limited	Rapid two-stage polymerase chain reaction method for detection of lactic acid bacteria in beer
JP2003510017A (ja)	1999-06-22	2003-03-18	インビトロジェンコーポレイション	核酸の検出および識別のために改良されたプライマーおよび方法
US6830902B1 (en)	1999-07-02	2004-12-14	Invitrogen Corporation	Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
CA2384838C (en)	1999-09-13	2006-07-18	Nugen Technologies, Inc.	Methods and compositions for linear isothermal amplification of polynucleotide sequences
US6692918B2 (en)	1999-09-13	2004-02-17	Nugen Technologies, Inc.	Methods and compositions for linear isothermal amplification of polynucleotide sequences
WO2001044457A2 (en)	1999-12-16	2001-06-21	Monsanto Technology Llc	Dna constructs for expression of heterologous polypeptides in plants
ATE455186T1 (de)	2000-06-26	2010-01-15	Nugen Technologies Inc	Methoden und zusammensetzungen zur auf transkription basierenden vervielfältigung von nukleinsäuren
US7846733B2 (en)	2000-06-26	2010-12-07	Nugen Technologies, Inc.	Methods and compositions for transcription-based nucleic acid amplification
WO2002048401A2 (en)	2000-12-11	2002-06-20	Alexion Pharmaceuticals, Inc.	Nested oligonucleotides containing hairpin for nucleic acid amplification
WO2002048402A2 (en)	2000-12-13	2002-06-20	Nugen Technologies, Inc.	Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof
US6794141B2 (en)	2000-12-22	2004-09-21	Arcturus Bioscience, Inc.	Nucleic acid amplification
US6635451B2 (en)	2001-01-25	2003-10-21	Abbott Laboratories	Desaturase genes and uses thereof
KR20030082535A (ko)	2001-03-09	2003-10-22	뉴젠 테크놀로지스 인코포레이티드	Ｒｎａ 서열의 증폭을 위한 방법 및 조성물
CA2439074A1 (en)	2001-03-09	2002-09-19	Nugen Technologies, Inc.	Methods and compositions for amplification of rna sequences
EP1950305A1 (de)	2001-05-09	2008-07-30	Monsanto Technology, LLC	Tyr-A-Gene und ihre Verwendung
BRPI0209536B1 (pt)	2001-05-09	2016-05-10	Monsanto Technology Llc	construto de dna que codifica transportador de adenilato em plantas e método para produzir planta com sementes tendo nível aumentado de tocoferol
US7291477B2 (en)	2001-07-03	2007-11-06	Xenotope Diagnostics, Inc.	Method and device for trichomonas detection
ATE448320T1 (de)	2001-09-19	2009-11-15	Alexion Pharma Inc	Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation
US7414111B2 (en)	2001-09-19	2008-08-19	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
US20030165859A1 (en)	2001-10-23	2003-09-04	Invitrogen Corporation	Primers and methods for the detection and discrimination of nucleic acids
US7211656B2 (en)	2002-01-30	2007-05-01	Abbott Laboratories	Desaturase genes, enzymes encoded thereby, and uses thereof
DE60333280D1 (de)	2002-05-15	2010-08-19	Monsanto Technology Llc	Verfahren zur erhöhung des samengewichtes in einer pflanze
US7273730B2 (en)	2002-05-24	2007-09-25	Invitrogen Corporation	Nested PCR employing degradable primers
EP1540009B1 (de)	2002-08-05	2011-09-28	Quanta Biosciences, Inc.	Verbesserte zusammensetzungen zur in-vitro-amplifikation von nukleinsäuren
US7205147B2 (en)	2002-09-23	2007-04-17	E.I. Du Pont De Nemours And Company	Nucleic acids encoding ryanodine receptors
US7094879B2 (en)	2002-10-02	2006-08-22	Abbott Laboratories	Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006523465A (ja)	2003-04-14	2006-10-19	ニューゲンテクノロジーズ，インコーポレイテッド	ランダムにプライミングされる複合プライマーを用いる大規模増幅
US7807874B2 (en)	2003-12-10	2010-10-05	Monsanto Technology Llc	Stress tolerant plants and methods thereof
EP1766023B1 (de)	2004-06-04	2010-09-01	Fluxome Sciences A/S	Stoffwechseltechnisch hergestellte zellen zur produktion mehrfach ungesättigter fettsäuren
US7456270B2 (en)	2004-09-01	2008-11-25	Abbott Laboratories	Δ6-desaturase genes and uses thereof
ES2345993T3 (es)	2004-09-14	2010-10-07	The Regents Of The University Of Colorado, A Body Corporate	Metodo para el tratamiento con bucindolol basado en direccionamiento genetico.
US7790363B2 (en)	2005-02-07	2010-09-07	Abbott Laboratories Inc.	Diagnostic test for vitamin B12
US8624027B2 (en)	2005-05-12	2014-01-07	Abbvie Inc.	Combination therapy for treating cancer and diagnostic assays for use therein
US8017103B2 (en)	2005-07-01	2011-09-13	Board Of Regents, The University Of Texas System	Methods and compositions to diagnose trichomonas infection
WO2007022335A1 (en)	2005-08-16	2007-02-22	Merlogen, Llc	Methods for identification of merle gene
US7939258B2 (en)	2005-09-07	2011-05-10	Nugen Technologies, Inc.	Nucleic acid amplification procedure using RNA and DNA composite primers
US7439028B2 (en)	2005-09-30	2008-10-21	Board Of Regents, The University Of Texas System	Methods and compositions to correlate Trichomonas infection with prostate cancer
PT1976877E (pt)	2005-11-30	2014-04-29	Abbvie Inc	Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
US7803567B2 (en)	2005-12-09	2010-09-28	Board Of Regents, The University Of Texas System	Methods and compositions for detecting trichomonas in a sample contacted with fixative
US7285388B1 (en)	2006-04-07	2007-10-23	Merlogen, Llc	Methods for identification of alport syndrome
US8933209B2 (en)	2006-04-26	2015-01-13	Abbvie Inc.	Dep2 and its uses in major depressive disorder and other related disorders
CA2976174C (en)	2006-05-25	2019-12-03	Monsanto Technology Llc	A method to identify disease resistant quantitative trait loci in soybean and compositions thereof
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Verfahren zur behandlung von amyloidosen
WO2009029771A2 (en)	2007-08-29	2009-03-05	Monsanto Technology Llc	Methods and compositions for breeding for preferred traits
US8034568B2 (en)	2008-02-12	2011-10-11	Nugen Technologies, Inc.	Isothermal nucleic acid amplification methods and compositions
US8030471B2 (en)	2008-03-06	2011-10-04	Abbott Laboratories	Plasmodium malariae and Plasmodium ovale genes and uses thereof
US8268981B2 (en)	2008-03-06	2012-09-18	Abbott Laboratories	Plasmodium malariae and plasmodium ovale genes and uses thereof
GB2470672B (en)	2008-03-21	2012-09-12	Nugen Technologies Inc	Methods of RNA amplification in the presence of DNA
CN104388568B (zh)	2008-04-24	2017-04-12	孟山都技术有限公司	鉴定大豆中亚洲大豆锈病抗性数量性状基因座的方法和其组合物
EP2358869B1 (de)	2008-10-06	2014-03-26	Abbott Laboratories	Delta-8-desaturasegene, von diesen kodierte enzyme und ihre verwendung
US8288124B2 (en)	2008-11-20	2012-10-16	Abbott Laboratories	Cloning, expression and purification of recombinant porcine intrinsic factor for use in diagnostic assay
EP2370568B1 (de)	2008-12-10	2017-07-19	Dana-Farber Cancer Institute, Inc.	Mek mutanten mit resistenz gegen mek inhibitoren
EP2479288A1 (de)	2009-01-31	2012-07-25	Abbott Laboratories	Marker zur Vorhersage und Überwachung der Reaktion auf eine Therapie mit einem Aurorakinase-B-Inhibitor
US9045800B2 (en)	2009-02-11	2015-06-02	Abbvie Inc.	Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers
US8063193B2 (en)	2009-03-27	2011-11-22	Abbott Laboratories	Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof
HRP20140887T1 (hr)	2009-05-14	2014-11-21	Arizona Board Of Regents On Behalf Of University Of Arizona	Dijagnoza karcinoma i lijeäśenje, koje se temelji na odc1 genotipu
JP2012531926A (ja)	2009-06-30	2012-12-13	アボットラボラトリーズ	Ｘｍｒｖ感染のマーカーとその使用
US8188335B2 (en)	2009-07-17	2012-05-29	Abbott Laboratories	Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
WO2011032088A1 (en)	2009-09-11	2011-03-17	Arca Biopharma, Inc.	Polymorphisms in the pde3a gene
WO2011079273A2 (en)	2009-12-23	2011-06-30	Arca Biopharma, Inc.	Methods and compositions for cardiovascular diseases and conditions
EP3028699B1 (de)	2010-02-25	2018-03-21	Dana-Farber Cancer Institute, Inc.	Braf-mutationen für resistenz gegen braf-inhibitoren
EP2545187B1 (de)	2010-03-09	2018-09-05	Dana-Farber Cancer Institute, Inc.	Verfahren zur diagnose und behandlung von krebs bei patienten mit resistenz bzw. entwicklung einer resistenz gegenüber einer ersten krebstherapie
EP2558494B1 (de)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta-bindende proteine
EP2568978B1 (de)	2010-05-14	2019-04-24	Arizona Board of Regents on Behalf of University of Arizona	Krebsvorbeugung und -behandlung basierend auf polyamin-nahrungsmittelgehalt
PT2580322T (pt)	2010-06-09	2018-03-01	Dana Farber Cancer Inst Inc	Uma mutação em mek1 que confere resistência aos inibidores de raf e mek
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白
WO2012024513A2 (en)	2010-08-18	2012-02-23	Abbott Laboratories	Molecular detection of xmrv infection
WO2012024518A1 (en)	2010-08-18	2012-02-23	Abbott Laboratories	Molecular detection of xmrv infection
WO2012149193A2 (en)	2011-04-29	2012-11-01	Monsanto Technology Llc	Diagnostic molecular markers for seed lot purity traits in soybeans
HUE059863T2 (hu)	2011-08-31	2023-01-28	Seminis Vegetable Seeds Inc	Eljárás és készítmények görögdinnye keménységhez
US10314253B2 (en)	2012-12-04	2019-06-11	Seminis Vegetable Seeds, Inc.	Methods and compositions for watermelon sex expression
US10294489B2 (en)	2013-03-15	2019-05-21	Board Of Trustees Of Southern Illinois University	Soybean resistant to cyst nematodes
US10059999B2 (en)	2013-06-10	2018-08-28	Monsanto Technology Llc	Molecular markers associated with soybean tolerance to low iron growth conditions
NZ767892A (en)	2013-11-27	2022-07-01	Seminis Vegetable Seeds Inc	Disease resistance loci in onion
PT3632202T (pt)	2014-02-21	2022-10-03	Syngenta Participations Ag	Locais genéticos associados a fertilidade acrescida em milho
NZ630710A (en)	2014-02-27	2016-03-31	Seminis Vegetable Seeds Inc	Compositions and methods for peronospora resistance in spinach
US10316369B2 (en)	2014-06-27	2019-06-11	Seminis Vegetable Seeds, Inc.	Methods and assays for male sterile watermelon
EP3005862A1 (de)	2014-10-10	2016-04-13	Seminis Vegetable Seeds, Inc.	Melonenpflanzen mit verbesserter krankheitstoleranz
US10448595B2 (en)	2015-09-03	2019-10-22	Seminis Vegetable Seeds, Inc.	Downy mildew resistant lettuce plants
EP3199642A1 (de)	2016-02-01	2017-08-02	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Pflanzenzucht mithilfe von sequenzierung mit grossem durchsatz
WO2017165732A1 (en)	2016-03-24	2017-09-28	Tragara Pharmaceuticals, Inc.	Treatment of cancer with tg02
AU2017250076B2 (en)	2016-04-12	2021-07-22	The Regents Of The University Of Michigan	Bet protein degraders
ES2857743T3 (es)	2016-09-13	2021-09-29	Univ Michigan Regents	1,4-diazepinas fusionadas como degradadores de proteína BET
CN110062759B (zh)	2016-09-13	2022-05-24	密执安大学评议会	作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
AU2017232187B2 (en)	2016-09-30	2023-11-09	Seminis Vegetable Seeds, Inc.	Xanthomonas resistant brassica oleracea plants
MX2020001759A (es)	2017-08-14	2020-12-10	Epizyme Inc	Inhibidores de histona acetiltransferasa de la familia myst.
EP3668876B1 (de)	2017-08-18	2024-01-24	Cothera Bioscience, Inc.	Polymorphe formen von tg02
US11267822B2 (en)	2017-09-13	2022-03-08	The Regents Of The University Of Michigan	BET bromodomain protein degraders with cleavable linkers
AU2019321464B2 (en)	2018-08-14	2025-03-27	Epizyme, Inc.	Substituted indoles and methods of use thereof
MX2021003999A (es)	2018-10-08	2021-06-23	Univ Michigan Regents	Moleculas de bajo peso molecular degradadoras de la proteina mdm2.
AU2020208190B2 (en)	2019-01-15	2022-07-28	Seminis Vegetable Seeds, Inc.	Green bean plants with improved disease resistance
US20220265590A1 (en)	2019-06-12	2022-08-25	Vanderbilt University	Dibenzylamines as amino acid transport inhibitors
AU2020291464A1 (en)	2019-06-12	2022-02-03	Vanderbilt University	Amino acid transport inhibitors and the uses thereof
US11542513B2 (en)	2019-09-26	2023-01-03	Seminis Vegetable Seeds, Inc.	Lettuce plants having resistance to Nasonovia ribisnigri biotype Nr:1
AU2021204717A1 (en)	2020-07-15	2022-02-03	Seminis Vegetable Seeds, Inc.	Green Bean Plants with Improved Disease Resistance
US20230193310A1 (en)	2021-12-10	2023-06-22	Seminis Vegetabe Seeds, Inc.	Lettuce plants having resistance to downy mildew
US20230404003A1 (en)	2022-06-21	2023-12-21	Seminis Vegetable Seeds, Inc.	Novel qtls conferring resistance to cucumber mosaic virus
MX2024004405A (es)	2023-04-14	2024-11-08	Seminis Vegetable Seeds Inc	Métodos y composiciones de resistencia a peronospora en la espinaca
US20260071285A1 (en)	2024-09-11	2026-03-12	Seminis Vegetable Seeds, Inc.	Novel qtls conferring resistance to cucurbit aphid-borne yellow virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3941876A (en) *	1973-04-25	1976-03-02	Gte New Ventures Corporation	In vitro method for determining allergic hypersensitivity
FR2233024A1 (en) *	1973-06-15	1975-01-10	Greyward Lab Interconti	Treponema haemagglutination test - using tanned avian erythrocytes as carrier for ireponema antigen
US3979509A (en) *	1974-09-03	1976-09-07	General Electric Company	Opaque layer method for detecting biological particles
US3952091A (en) *	1974-10-23	1976-04-20	Hoffmann-La Roche Inc.	Simultaneous multiple radioimmunoassay
US4237224A (en) *	1974-11-04	1980-12-02	Board Of Trustees Of The Leland Stanford Jr. University	Process for producing biologically functional molecular chimeras
US4094759A (en) *	1975-01-03	1978-06-13	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Method for simultaneous quantitative analysis of several constituents in a sample
US4097149A (en) *	1975-02-03	1978-06-27	Aladjem Frederick J	Quantitative protein analysis by immunodiffusion
FR2353856A1 (fr) *	1976-06-02	1977-12-30	Chateau Guy	Ruban destine a servir de support a une reaction par exemple chimique ou biochimique, et procede d'analyse le mettant en oeuvre
US4294817A (en) *	1977-11-25	1981-10-13	International Diagnostic Technology, Inc.	Method of fluoro immunoassay
EP0017460A1 (de) *	1979-04-02	1980-10-15	Research Corporation	Immunofluoreszenz-Testmethode und Substanz zur Verwendung darin

1981
- 1981-09-22 JP JP56503335A patent/JPS57501692A/ja active Pending
- 1981-09-22 BR BR8108820A patent/BR8108820A/pt unknown
- 1981-09-22 WO PCT/US1981/001272 patent/WO1982001011A1/en not_active Ceased
- 1981-09-22 IL IL63907A patent/IL63907A0/xx unknown
- 1981-09-23 ES ES505713A patent/ES505713A0/es active Granted
- 1981-09-24 EP EP81304411A patent/EP0050424B1/de not_active Expired
- 1981-09-24 CA CA000386624A patent/CA1167376A/en not_active Expired
- 1981-09-24 DE DE8181304411T patent/DE3172347D1/de not_active Expired
1982
- 1982-05-12 NO NO821569A patent/NO821569L/no unknown
- 1982-05-24 DK DK232882A patent/DK232882A/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1982001011A1 (en)	1982-04-01
ES8303072A1 (es)	1983-02-01
BR8108820A (pt)	1982-08-24
JPS57501692A (de)	1982-09-16
EP0050424B1 (de)	1985-09-18
IL63907A0 (en)	1981-12-31
CA1167376A (en)	1984-05-15
ES505713A0 (es)	1983-02-01
DE3172347D1 (en)	1985-10-24
DK232882A (da)	1982-05-24
EP0050424A1 (de)	1982-04-28

Publication	Publication Date	Title
EP0050424B1 (de)	1985-09-18	Verfahren zur Herstellung eines analytischen Reagenzes zur Bestimmung von Antikörpern, analytisches Reagenz und Verfahren zur Bestimmung von Antikörpern in einer Probe
Teysseire et al.	1992	Comparison of Western immunoblotting and microimmunofluorescence for diagnosis of Mediterranean spotted fever
Gussenhoven et al.	1997	LEPTO dipstick, a dipstick assay for detection of Leptospira-specific immunoglobulin M antibodies in human sera
Clements et al.	1983	Serodiagnosis of Rocky Mountain spotted fever: comparison of IgM and IgG enzyme-linked immunosorbent assays and indirect fluorescent antibody test
Karlsson et al.	1989	Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis
JPH05264553A (ja)	1993-10-12	ヘリコバクターピロリ検出用の抗原調製物
Kim et al.	1993	Rapid diagnosis of scrub typhus by a passive hemagglutination assay using recombinant 56-kilodalton polypeptides
Robinson et al.	1993	Analysis of the humoral response to the flagellin protein of Borrelia burgdorferi: cloning of regions capable of differentiating Lyme disease from syphilis
Nielsen et al.	1987	An enzyme labelled nuclear antigen immunoassay for detection of cytomegalovirus IgM antibodies in human serum: specific and non‐specific reactions
Abd-Alla et al.	1998	Serum IgM antibody response to the galactose-inhibitable adherence lectin of Entameoba histolytica.
Marangoni et al.	2000	Treponema pallidum surface immunofluorescence assay for serologic diagnosis of syphilis
US5643733A (en)	1997-07-01	Borrelia burgdorferi antigens and uses thereof
US10859575B2 (en)	2020-12-08	Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
Litwin et al.	1997	Immunologic response to Bartonella henselae as determined by enzyme immunoassay and Western blot analysis
Karlsson	1990	Western immunoblot and flagellum enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis
Dettori et al.	1989	Evaluation of Western immunoblotting technique in the serological diagnosis of human syphilitic infections
EP0165658A2 (de)	1985-12-27	Verfahren und Zuammensetzungen zum Nachweis der Legionärskrankheit
EP1240519B1 (de)	2007-01-31	Kompositionen und verfahren zum nachweis von treponema pallidum
EP4136251A1 (de)	2023-02-22	Nachweis der lyme-krankheit
Verhofstede et al.	1989	Comparison of six commercial enzyme linked immunosorbent assays for detecting IgM antibodies against Toxoplasma gondii.
US5374520A (en)	1994-12-20	Assay method for Epstein-Barr virus antibodies
Rauer et al.	1995	Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease
WO1996007910A1 (en)	1996-03-14	Diagnostic drug for chlamydia infection
Jones et al.	1993	Enzyme-linked immunosorbent assay for detection of human immunoglobulin G to lipopolysaccharide of spotted fever group rickettsiae
Cutler et al.	1994	Predictive value of serology in diagnosing Lyme borreliosis.